Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.

Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F.

Clin Pharmacol Ther. 1992 Apr;51(4):388-97. Erratum in: Clin Pharmacol Ther 1994 Jun;55(6):648.

PMID:
1345344
[PubMed - indexed for MEDLINE]
2.

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA.

Clin Pharmacol Ther. 1985 Oct;38(4):402-8.

PMID:
4042523
[PubMed - indexed for MEDLINE]
3.

Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.

Marandi T, Dahl ML, Kiivet RA, Rägo L, Sjöqvist F.

Pharmacol Toxicol. 1996 May;78(5):303-7.

PMID:
8737964
[PubMed - indexed for MEDLINE]
4.

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.

Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L.

Pharmacogenetics. 1996 Oct;6(5):441-7.

PMID:
8946476
[PubMed - indexed for MEDLINE]
5.

Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects.

Zhang YA, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L.

Clin Pharmacol Ther. 1990 Nov;48(5):496-502.

PMID:
2225709
[PubMed - indexed for MEDLINE]
6.

Polymorphic debrisoquin metabolism in a Turkish population.

Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO.

Clin Pharmacol Ther. 1994 Apr;55(4):399-401.

PMID:
8162666
[PubMed - indexed for MEDLINE]
7.

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.

Sanz EJ, Villén T, Alm C, Bertilsson L.

Clin Pharmacol Ther. 1989 May;45(5):495-9.

PMID:
2721104
[PubMed - indexed for MEDLINE]
8.

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, Chiba K.

Clin Pharmacol Ther. 1992 Aug;52(2):160-9.

PMID:
1505151
[PubMed - indexed for MEDLINE]
9.

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.

Dahl ML, Tybring G, Elwin CE, Alm C, Andreasson K, Gyllenpalm M, Bertilsson L.

Clin Pharmacol Ther. 1994 Aug;56(2):176-83.

PMID:
8062494
[PubMed - indexed for MEDLINE]
10.

Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.

Caraco Y, Wilkinson GR, Wood AJ.

Clin Pharmacol Ther. 1996 Oct;60(4):396-404.

PMID:
8873687
[PubMed - indexed for MEDLINE]
11.

Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.

Wang SL, Huang JD, Lai MD, Liu BH, Lai ML.

Clin Pharmacol Ther. 1993 Apr;53(4):410-8.

PMID:
8097442
[PubMed - indexed for MEDLINE]
12.

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA.

Clin Pharmacol Ther. 1984 Dec;36(6):773-80.

PMID:
6499356
[PubMed - indexed for MEDLINE]
13.

Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.

de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH.

Clin Pharmacol Ther. 1995 Oct;58(4):404-11.

PMID:
7586932
[PubMed - indexed for MEDLINE]
14.

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM.

Clin Pharmacol Ther. 1989 Aug;46(2):198-207.

PMID:
2758729
[PubMed - indexed for MEDLINE]
15.

Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.

Kiivet RA, Svensson JO, Bertilsson L, Sjöqvist F.

Pharmacol Toxicol. 1993 Feb;72(2):113-5.

PMID:
8474964
[PubMed - indexed for MEDLINE]
16.

Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.

Yasumori T, Murayama N, Yamazoe Y, Kato R.

Clin Pharmacol Ther. 1990 Mar;47(3):313-22.

PMID:
2311333
[PubMed - indexed for MEDLINE]
17.

Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.

Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL.

Clin Pharmacol Ther. 1979 Nov;26(5):584-91.

PMID:
498701
[PubMed - indexed for MEDLINE]
18.

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Küpfer A, Preisig R.

Eur J Clin Pharmacol. 1984;26(6):753-9.

PMID:
6489416
[PubMed - indexed for MEDLINE]
19.

CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.

He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, Zhou HH.

Eur J Clin Pharmacol. 2002 Apr;58(1):15-8. Epub 2002 Feb 22.

PMID:
11956668
[PubMed - indexed for MEDLINE]
20.

[Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers].

Kuang TY, Liao XM, Wang KY, Zhang Y, Lou YQ.

Yao Xue Xue Bao. 1991;26(4):250-4. Chinese.

PMID:
1957669
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk